We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sarepta Inks Manufacturing Deal for Gene Therapy Program
Read MoreHide Full Article
Sarepta Therapeutics, Inc. (SRPT - Free Report) announced that it has entered into a long-term strategic manufacturing partnership with privately-held Brammer Bio for the manufacturing and commercial supply of its potential micro-dystrophin gene therapy and other neuromuscular pipeline products.
The partnership will help Sarepta to focus on process development by leveraging Brammer Bio’s world-class manufacturing capabilities for clinical and commercial supply of its micro-dystrophin Duchenne muscular dystrophy (“DMD”) gene therapy products. Sarepta will also access Brammer Bio’s manufacturing facilities for future gene therapy programs such as Limb girdle muscular dystrophy (“LGMD”).
Sarepta is planning to initiate clinical studies to evaluate gene therapies by mid-2018.
Brammer Bio is a biotech company, which provides services for development and early phase to commercial manufacturing services for cell and gene therapies.
So far this year, Sarepta’s shares have rallied 73.9% against a 6.5% decrease registered by the industry. The rally can be attributed to strong product sales and its key pipeline candidate’s progress.
Sarepta has only one product in its commercial portfolio, Exondys 51, which is available for the treatment of DMD in the United States. The drug has performed well in 2017, generating sales of more than $150 million in its first full year of commercialization. The sales are expected to double in 2018. The drug is under review in EU.
Moreover, Sarepta’s most advanced pipeline candidate, golodirsen, demonstrated encouraging results in a mid-stage clinical study evaluating it in DMD patients. The candidate has also shown better efficacy than Exondys 51. Sarepta is planning to file regulatory application seeking golodirsen’s approval in the United States by the end of this year.
Apart from golodirsen, there are several other DMD candidates in early to mid-stage studies.
We remind investors that Pfizer (PFE - Free Report) is also developing a gene therapy for the treatment of DMD. An early-stage study was initiated in April.
Aeglea’s loss estimates narrowed from $1.93 to $1.67 for 2018 and from $3.86 to $3.57 for 2019 over the last 60 days. The company delivered positive earnings surprise in three of the trailing four quarters with an average beat of 19.32%. Its share price has increased 86.5% so far this year.
ANI Pharmaceuticals’ earnings estimates increased from $5.54 to $5.79 for 2018 and from $5.72 to $5.80 for 2019 over the last 60 days. The company came up with a positive earnings surprise in three of the four trailing quarters with an average beat of 8.69%.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
Sarepta Inks Manufacturing Deal for Gene Therapy Program
Sarepta Therapeutics, Inc. (SRPT - Free Report) announced that it has entered into a long-term strategic manufacturing partnership with privately-held Brammer Bio for the manufacturing and commercial supply of its potential micro-dystrophin gene therapy and other neuromuscular pipeline products.
The partnership will help Sarepta to focus on process development by leveraging Brammer Bio’s world-class manufacturing capabilities for clinical and commercial supply of its micro-dystrophin Duchenne muscular dystrophy (“DMD”) gene therapy products. Sarepta will also access Brammer Bio’s manufacturing facilities for future gene therapy programs such as Limb girdle muscular dystrophy (“LGMD”).
Sarepta is planning to initiate clinical studies to evaluate gene therapies by mid-2018.
Brammer Bio is a biotech company, which provides services for development and early phase to commercial manufacturing services for cell and gene therapies.
So far this year, Sarepta’s shares have rallied 73.9% against a 6.5% decrease registered by the industry. The rally can be attributed to strong product sales and its key pipeline candidate’s progress.
Sarepta has only one product in its commercial portfolio, Exondys 51, which is available for the treatment of DMD in the United States. The drug has performed well in 2017, generating sales of more than $150 million in its first full year of commercialization. The sales are expected to double in 2018. The drug is under review in EU.
Moreover, Sarepta’s most advanced pipeline candidate, golodirsen, demonstrated encouraging results in a mid-stage clinical study evaluating it in DMD patients. The candidate has also shown better efficacy than Exondys 51. Sarepta is planning to file regulatory application seeking golodirsen’s approval in the United States by the end of this year.
Apart from golodirsen, there are several other DMD candidates in early to mid-stage studies.
We remind investors that Pfizer (PFE - Free Report) is also developing a gene therapy for the treatment of DMD. An early-stage study was initiated in April.
Sarepta Therapeutics, Inc. Price
Sarepta Therapeutics, Inc. Price | Sarepta Therapeutics, Inc. Quote
Zacks Rank & Stocks to Consider
Sarepta currently carries a Zacks Rank #4 (Sell).
A couple of better-ranked stocks in the pharma sector include Aeglea BioTherapeutics, Inc. and ANI Pharmaceuticals, Inc. (ANIP - Free Report) . Both the stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Aeglea’s loss estimates narrowed from $1.93 to $1.67 for 2018 and from $3.86 to $3.57 for 2019 over the last 60 days. The company delivered positive earnings surprise in three of the trailing four quarters with an average beat of 19.32%. Its share price has increased 86.5% so far this year.
ANI Pharmaceuticals’ earnings estimates increased from $5.54 to $5.79 for 2018 and from $5.72 to $5.80 for 2019 over the last 60 days. The company came up with a positive earnings surprise in three of the four trailing quarters with an average beat of 8.69%.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>